Abstract
Mammary analogue secretory carcinoma (MASC) is a recently described salivary gland tumor, with a limited number of published reports. Less than three hundred cases have been reported in the literature and only 18 of these cases have been reported in minor palatal salivary glands, though publication bias is likely a factor. We present a case of a 57-year-old male who was diagnosed with MASC tumor presenting in a minor salivary gland and briefly review the current literature. MASC has a variety of histological features and different range of clinical behaviors. The histopathological diagnosis of MASC can be difficult, and the immunohistochemical profile of MASC is still being updated. The gold standard for MASC diagnosis is cytogenetics, with the majority having a translocation t(12;15)(p133;q25). Presently, there is no conclusive evidence that MASC should be treated differently than any other low-grade malignant salivary gland tumors, though high-grade transformation has been described.
Highlights
Mammary analogue secretory carcinoma (MASC) is a rare salivary gland neoplasm that was first reported in 2010 by Skalova et al [1]
It occurs primarily in adolescent women [2]. Both MASC and breast secretory carcinoma are associated with translocation t(12;15)(p13;q25), which is a fusion of the ETV6 gene on chromosome 12 and the NTRK3 gene on chromosome 15
The financial burden of this cytogenetic test can be prohibitive for some institutions, and there have been reports of cases not demonstrating ETV6-NTRK3 fusion gene but were diagnosed as MASC based on the results of immunohistochemistry [6]
Summary
Mammary analogue secretory carcinoma (MASC) is a rare salivary gland neoplasm that was first reported in 2010 by Skalova et al [1]. 16 cases of salivary gland tumors were reexamined and were found to have similar histological and molecular features as breast secretory carcinoma. It occurs primarily in adolescent women [2] Both MASC and breast secretory carcinoma are associated with translocation t(12;15)(p13;q25), which is a fusion of the ETV6 gene on chromosome 12 and the NTRK3 gene on chromosome 15. The financial burden of this cytogenetic test can be prohibitive for some institutions, and there have been reports of cases not demonstrating ETV6-NTRK3 fusion gene but were diagnosed as MASC based on the results of immunohistochemistry [6].
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
